Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508908 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL19927661 | 0.93 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL30613047 | 0.88 | CYP1A2 (0.38) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL517768 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL29661436 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL14346488 | 0.86 | HSPB1 (0.40) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL15744027 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL31757016 | 0.85 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL30801468 | 0.85 | ALDH1A1 (0.48) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL12458650 | 0.85 | ALDH1A1 (0.48) | ALDH1A1TDP1MAPTKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2026-01-22 | — | — | US | disclosed |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025067509-A1 | EGFR DEGRADANT, AND PREPARATION METHOD AND USE THEREFOR | 石药集团中奇制药技术（石家庄）有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4506343-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | VORONOI INC. (KR) | 2024-11-21 | — | — | US | disclosed |
| CN-118946557-A | Heteroaryl derivatives and uses thereof | 株式会社沃若诺伊 | 2024-11-12 | — | — | CN | disclosed |
| US-20240360102-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | PHARMACIA & UPJOHN COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | PHARMACIA & UPJOHN COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050239849-A1 | Useful for therapy of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20030036558-A1 | Substituted phenoxyacetic acids | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. | 2003-02-20 | — | — | US | disclosed |
| US-6420426-B1 | USED TO TREAT COMPLICATIONS FROM DIABETES MELLITUS | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2002-07-16 | — | — | US | disclosed |
| EP-1198451-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001000566-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | SLC5A2, GPR119, SLC5A1 | ALDH1A1 432/4885TDP1 3406/4885MAPT 2825/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | ALDH1A1 2560/4885TDP1 1407/4885MAPT 89/4885 |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | ALDH1A1 2593/4885TDP1 4147/4885MAPT 2724/4885 |
| US-20050239849-A1 | Useful for therapy of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor | ACE, DNPEP, AGT | ALDH1A1 224/4885TDP1 1915/4885MAPT 1176/4885 |
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | ALDH1A1 4593/4885TDP1 2988/4885MAPT 72/4885 |
| US-20240360102-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | WEE1, WEE2, EGFR | ALDH1A1 697/4885TDP1 665/4885MAPT 3170/4885 |
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | ERBB2, ERBB3, EGFR | ALDH1A1 955/4885TDP1 4156/4885MAPT 2826/4885 |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | NAMPT, NAPRT, NNT | ALDH1A1 789/4885TDP1 3871/4885MAPT 1402/4885 |
| US-20030036558-A1 | Substituted phenoxyacetic acids | SLC5A2, GPR119, SLC5A1 | ALDH1A1 432/4885TDP1 3406/4885MAPT 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.